Board of Directors

Mr. Chee has served as the Executive Chairman of our board of directors since September 2025. He has been a Founder and Chairman of Summer Capital Limited since August 2017. Summer Capital is an investment company dedicated to investing in early growth state companies in “new economy” sectors such as fintech, blockchain infrastructure and application, consumption technology and healthcare. He has also served as the Vice Chairman of AMINA Bank AG, a company focused on providing a bridge between traditional finance and digital assets while operating as a FINMA-regulated cryptocurrency bank and offering services such as secure custody, crypto trading, staking, lending, asset management and tokenized products to professional investors, corporations, family offices and institutions globally, since April 2020. In addition, Mr. Chee is the founder of Summer Healthcare Fund, L.P. since February 2021 and Summer Everest Ecosystem Fund, L.P. since September 2023. Each are investment companies focused on healthcare and biotechnology and blockchain ecosystem and financial technology, respectively. Prior to these positions, Mr. Chee was Head of Investment Banking and Head of Global Capital Markets, Asia at UBS AG. From 2000 to 2017, Mr. Chee held a number of positions in UBS AG. Mr. Chee has earned a Doctorate degree in applied finance from the University of Geneva, an Executive Master of Business Administration degree Tsinghua University, a Master of Business Administration degree from New York University and a Bachelor’s degree in mechanical engineering from Stevens Institute of Technology.

Mr. Andreeff has served as our President and Chief Executive Officer since June 2021 after having served as our Interim President and Chief Executive Officer from August 2020 until June 2021. He has also served as a member of our Board of Directors since August 2017. Mr. Andreeff is the General Partner and Portfolio Manager at Maple Leaf Partners, LP. Maple Leaf Partners, LP is a hedge fund founded by Mr. Andreeff, where he has been employed since 1996. In 2003, the fund was seeded by Julian Robertson’s Tiger Management and later grew to over $2 billion in assets under management. Mr. Andreeff also serves as a member of the board of directors of privately-held HDL Therapeutics, Inc. and Myocardial Solutions, Ltd. Mr. Andreeff received his Bachelor’s degree in Economics from the University of Texas at Arlington in 1989 and his Master’s degree in Economics from the University of Texas at Arlington in 1991.

Cosmo Jiang is a General Partner at Pantera Capital, where he leads the firm’s Digital Asset Treasury investment practice. He brings more than a decade of experience spanning digital assets, hedge funds, and private equity, with a track record of building and managing investment strategies across both traditional and emerging markets. Before joining Pantera, he was Managing Partner at Nova River, a digital asset fund, and previously served as Managing Director at Hitchwood Capital. His earlier career includes roles at Apollo Global Management and Evercore, and he holds a B.A. in Applied Mathematics from Harvard University.

Mr. Walter is a partner at Talisman Capital Partners, a private investment partnership located in Columbus, Ohio.

Mr. Walter was the founder of inChord Communications, Inc, which he built into the largest independently owned, healthcare communications company in the world. In 2005, inChord was acquired by Ventiv Health, the largest provider of outsourced sales and clinical services serving the pharmaceutical industry to create inVentiv Health. In 2008, Mr. Walter became chief executive officer of the combined public company.

Through organic growth and more than 20 acquisitions, inVentiv Health became the leading provider of outsourced product development and commercialization services to the global pharmaceutical and life sciences industries. inVentiv’s client roster consists of more than 350 leading pharmaceutical, biotech, life sciences, and healthcare payer companies. In 2010, Mr. Walter led the successful $1.2 billion buyout of inVentiv Health by Thomas H. Lee Partners. Mr. Walter presently serves as vice chairman of inVentiv Health and also serves as chairman of the Governor of Ohio’s Executive Workforce Board.

Before joining inChord, Mr. Walter worked as a financial analyst in New York City for Smith Barney in a mergers and acquisitions specialty group. Mr. Walter actively pursues and oversees investments in healthcare, information technology, and marketing/professional services.

Mr. Walter graduated summa cum laude with a Bachelor of Science degree in Marketing and Finance from Boston College.

Mr. Straw is the founder and managing partner of Osprey Venture Partners—a firm that finds investment capital and assists with business development for startup entrepreneurs. He is the retired president, Global Operations of The Estee Lauder Companies, and currently sits on the boards of the following companies: Academy Securities, Boston Consulting Group Federal, Odyssey Logistics, Solana Company, and Lenitiv Scientific. He is the chairman of Odyssey Logistics.

During his 10 years as chairman of Odyssey, he has overseen the valuation of the company grow from $40M to $1.5B.

As president, Global Operations for Estee Lauder, Mr. Straw led Lauder’s research and development, package engineering, acquisition, manufacturing, distribution, inventory management, and information systems organizations that supported 20 Estee Lauder Companies around the world. In his 5 years at Estee Lauder, he is credited with directing significant improvements in their global supply chain and driving major stock price, impacting savings to the bottom line.

Before joining the Estee Lauder Companies, he was senior vice president, Global Manufacturing and Supply Chain Management at the $40 billion Compaq Computer Corporation in Houston. Before joining Compaq in late 1998, Mr. Straw was president of Miami-based Ryder Integrated Logistics— then the leading provider of third-party supply chain services in North America.

Ms. Perkins currently serves as a member of the Venture Mentoring Service at the University of Texas MD Anderson Cancer Center, providing guidance and perspective on commercialization-related topics that are important and relevant to the progression of various ventures. From 2017 to 2019, Ms. Perkins served as a consultant to LivaNova, PLC (NASDAQ: LIVN), a global medical technology company that designs, develops, manufactures, and sells innovative therapeutic solutions in the fields of neuromodulation and cardiovascular disease. She previously spent 17 years at LivaNova and its affiliates in several roles, including serving as vice president in the sleep apnea, new ventures space within the company from 2015 to 2017, and as vice president of Marketing and New Business Development of Cyberonics, Inc. from 2011 to 2015.

Ms. Perkins received a BS in Medical Technology from Mississippi State University and an MA in Management from Central Michigan University.

Mr. Buckman is currently the president of LivaNova, PLC, for North America. Before joining LivaNova, Mr. Buckman served as chief executive officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation from September 2013 until March 2017. Mr. Buckman was chief executive officer of SentreHEART, Inc, a medical technology company focused on closure of various anatomic structures from February 2012 to September 2013.

Previously, Mr. Buckman served as chief executive officer and chairman of Pathway Medical Technologies, Inc, a medical device company focused on treatment of peripheral arterial disease from September 2008 to February 2012; as chief executive officer of Devax, Inc, a developer and manufacturer of drug-eluting stents from December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc, a publicly traded diversified medical products company from August 2004 to December 2006; and as chairman of the board of directors and chief executive officer of ev3, LLC, a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman founded and developed into an $80 million business from January 2001 to January 2004. Mr. Buckman has worked in the medical device industry for over 30 years, including 10 years at Scimed Life Systems, Inc and Boston Scientific Corporation, a publicly traded medical device manufacturer, where he held several executive positions before becoming president of the cardiology division of Boston Scientific in January 2000. Mr. Buckman also currently serves as a director for NeuroOne, Inc (chairman), Ablative Solutions, Inc, ActivOrtho, Shoulder Innovations, and Miromatrix, Inc (chairman). He previously served as a director of Conventus Orthopaedics, Caisson Interventional LLC, Velocimed, Inc, where he was a co-founder, EndiCor, Inc, Microvena, Inc, Sunshine Heart, Inc, a publicly held early-stage medical device company, NexGen Medical, and Micro Therapeutics, Inc In addition to having raised in excess of $500M in private capital, the combined exit value of those companies in which Mr. Buckman has served as either chief executive officer, director or cofounder is approximately $2.8B. Mr. Buckman received a Master’s degree in Business Administration and Finance and a Bachelor’s degree in Business Administration from Western Michigan University.